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With the widespread adoption of population-based breast cancer screening, ductal carcinoma in situ
(DCIS) has come to represent 20e25% of all breast neoplastic lesions diagnosed. Current treatment aims
at preventing invasive breast cancer, but the majority of DCIS lesions will never progress to invasive
disease. Still, DCIS is treated by surgical excision, followed by radiotherapy as part of breast conserving
treatment, and/or endocrine therapy. This implies over-treatment of the majority of DCIS, as less than 1%
of DCIS patients will go on to develop invasive breast cancer annually. If we are able to identify which
DCIS is likely to progress or recur as invasive breast cancer and which DCIS would remain indolent, we
can treat the ﬁrst group intensively, while sparing the second group from such unnecessary treatment
(surgery, radiotherapy, endocrine therapy) preserving the quality of life of these women. This review
summarizes our current knowledge on DCIS and the risks involved regarding progression into invasive
breast cancer. It also shows current knowledge gaps, areas where profound research is highly necessary
for women with DCIS to prevent their over-treatment in case of a harmless DCIS, but provide optimal
treatment for potentially hazardous DCIS.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Since the introduction of population-based breast cancer
screening and digital mammography, the incidence of precursor
lesions has substantially increased in the Westernworld, without a
decline in invasive breast cancer incidence. This suggests that
overdiagnosis of such lesions exists. Most precursor lesions are
ductal carcinoma in situ (DCIS) cases. DCIS of the breast represents
a heterogeneous group of neoplastic lesions conﬁned to the breast
ducts and lobules that differ in histologic appearance and biological
potential.
The major gap in our current understanding of DCIS is, that we
do not know yet which DCIS lesions will develop into invasive
breast cancer and which will not. As a consequence, women withgy, Divisions of Diagnostic
ancer InstituteeAntoni van
sterdam, The Netherlands.
Ltd. This is an open access article u
t al., Finding the balance betw
ast.2016.09.001low risk DCIS face being harmed by intensive treatment without
any beneﬁt. If such overtreatment can be avoided without
compromising the excellent outcomes presently achieved, this will
safely spare many women with low risk DCIS intensive treatment
and so preserve their quality of life.
Here, we summarize our current understanding of DCIS and the
challenges that lie ahead of us to ﬁnd the balance between DCIS
over- and under-treatment.DCIS incidence has increased over time
In the United States (US), the incidence of DCIS markedly
increased from 5.8 per 100,000 women in the 1970s to 32.5 per
100,000 women in 2004 and then reached a plateau [1]. Approxi-
mately 25% of breast neoplastic lesions diagnosed in the US
are DCIS, i.e. over 51,000 women in the US alone in 2015 [2].
In the Netherlands and the UK, similar rates apply (www.
cijfersoverkanker.nl; www.cancerresearchuk.org/). This increase is
attributed primarily to the widespread adoption of mammographicnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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countries that has dramatically increased the number of DCIS
cases, as more than 90% of all cases of DCIS are detected only on
imaging studies [1].
DCIS is less common than invasive breast cancer. Like invasive
breast cancer, the risk increases with age. DCIS is uncommon in
women younger than 30. In the US, the rate of DCIS increases with
age from 0.6 per 1000 screening examinations in women aged
40e49 years to 1.3 per 1000 screening examinations in women
aged 70e84 years [4]. Risk of development of metastases and/or
death in a patient diagnosed with pure DCIS is very low (<1%) [5].
The risk factors for DCIS and invasive breast cancer are similar,
and include family history of breast cancer, increased breast den-
sity, obesity, and nulliparity or late age at ﬁrst birth [6e9]. DCIS is
also a component of the inherited breast-ovarian cancer syndrome
deﬁned by deleterious mutations in BRCA1 and BRCA2 genes;
mutation rates, i.e. up to 5%, are similar to those for invasive breast
cancer [9].
Over-treatment of DCIS exists
Increasing DCIS incidence is due mostly to introduction and
uptake of population-based breast cancer screening [1,10e12] and
use of digital mammography. The latter detecting signiﬁcantly
more DCIS lesions [13,14]. In the Netherlands, the incidence of in
situ lesions has increased 5.6-fold between 1989 and 2011 (www.
cijfersoverkanker.nl). Higher screening sensitivity also labels more
women as having disease, many of whom may never develop
invasive cancer [15,16]. However, the incidence of advanced breast
cancer has not decreased, despite screening [13,17]. In addition,
there is strong evidence that treatment of DCIS in most women has
no clear effect on mortality reduction [18].
This suggests overdiagnosis and hence overtreatment exists of
DCIS in general, and of low-grade DCIS in particular. The implica-
tion is that we could manage a subgroup of womenwith low-grade
DCIS using active surveillance only [11,19,20]. The number of
women eligible for this management strategy would be high, since
80% of all in situ carcinomas are DCIS lesions, and about 20% of all
DCIS lesions is low grade [21,22]. Fig. 1 illustrates the heteroge-
neous course of cancer, including its preliminary stages.
Remarkably, a lesion with a similar risk of progression to inva-
sive breast cancer is classic lobular carcinoma in situ [23,24]. If LCIS
is the only ﬁnding, active surveillance is frequently offered.
Somewhat incongruously, this risk is acceptable for both patients
and clinicians.Fig. 1. Heterogeneity of cancer progression in general. Fast growing cancers are likely to le
growing cancers may lead to symptoms, and maybe death, after many years. The very slowl
such a lesion are likely to die due to other causes. This is also true for non-progressive lesi
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Only 10% of DCIS cases is detected due to symptoms, such as
nipple discharge, Paget's disease of the nipple, or a palpable mass
[1]. As pointed out above, the majority of DCIS lesions found are
detected by screening, as many DCIS lesions do not come with
symptoms, but do contain calciﬁcations that can be seen upon
mammography. Obviously, DCIS lesions may be occult by
mammography or the diameter of the area containing calciﬁcations
underestimates the extent of DCIS [25,26]. This is also illustrated by
the much higher prevalence of DCIS (7e39%) found in autopsy
studies concerning the age group for which population-based
screening programs are in place, whereas in screening and clin-
ical practice breast cancer was diagnosed in only 1% of women
within a similar age range [21,27].
The natural course of DCIS is poorly understood
A multitude of factors have been implicated in the risk of
developing an in situ or invasive recurrence [28]. It has been sug-
gested that paracrine regulation is crucial for malignantly trans-
formed luminal cells to become invasive [29]. By analysing stromal
expression signatures in DCIS, it was shown that the microenvi-
ronment plays a role in the transition from pre-invasive to invasive
growth [30,31]. The myoepithelium is considered as a factor pre-
venting invasive growth by regulating luminal cell polarity, ductal
morphogenesis, and basement membrane deposition. In DCIS, the
myoepithelium shows decreased expression of e.g. thrombo-
spondin, laminin, and oxytocin, promoting proliferation, migration,
invasion, and angiogenesis [32,33]. It is uncertain whether changes
in stroma and/or myoepithelium precede invasive growth or that
the luminal DCIS cells can induce stromal and/or myoepithelial
changes, and thereby paving the way for their own invasion.
The pathology of DCIS provides limited prognostic value
The pathology of DCIS aims to assess subtype and grade. Addi-
tionally, pathology will report on extent and margin status in case
of surgical resection of DCIS. These aspects provide important
prognostic information about the ‘aggressiveness’ of a particular
DCIS lesion. DCIS is morphologically described by growth pattern,
i.e. arrangement of the ductal cells, such as cribriform, solid,
micropapillary, etc., cytoplasmic features, degree of nuclear pleo-
morphism, and degree of mitotic activity. Grading systems for DCIS
are based on these cytonuclear features resulting in low (1),ad to symptoms, and even death, after a relatively short period of time, whereas slow
y proliferating lesions most likely never lead to symptoms, implying that patients with
ons that might even regress. Adapted from Welch and Black [16].
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DCIS grading has some limitations, as diagnostic criteria are not
always clear. Furthermore, poor to modest interobserver agree-
ment exists, as has been reported in subgroups of in situ lesions,
which is mainly due to differences in morphological interpretation
and ﬁeld selection in the often heterogeneous intraductal lesions
[35e39]. Obviously, it is of utmost importance to classify the pri-
mary lesion reliably to be able to evaluate the natural course of DCIS
or to interpret follow-up after treatment. Reliability studies are
hard to compare as they often differ in study design. Also they are
limited due to: mostly examining a small number of highly selected
cases [35,40e45]; being assessed by expert breast pathologists only
and; often after being giving instructions or tutorials beforehand
[35,41,42,45,46]. Translation of these ﬁndings into daily practice is
therefore questionable and, so far, has not reduced inter-observer
variability. In addition, the interpretation of results and evalua-
tion of potential bias is complicated by often inadequate reporting
and missing information on important issues in reliability testing.
In 2011, guidelines for reporting reliability and agreement studies
were developed, highlighting key methodological issues that
should be carefully thought through when reporting on reliability
and agreement studies [47].
A recent study used exactly these guidelines to construct their
study design [48]. In this study 115 pathologists each classiﬁed a set of
60 cases as either benign without atypia, atypia, DCIS, or invasive
carcinoma. They found an overall concordance rate of 75%, and
concordance rates of 48% and 84% for atypia and DCIS respectively,
when compared with expert reference diagnoses. The concordance
rate for invasive breast cancer was excellent (96%). Test cases were
randomly selected, oversampling atypia and DCIS cases, and the
participating pathologists had different geographic and clinical setting
backgrounds leaving little room for selection bias. Unfortunately, as
‘gold standard’ they used consensus-derived expert diagnoses
without any information on follow up. Whether such results on
concordance are biologically relevant, therefore remain unanswered.
Although inter-observer variability may lead to overtreatment
of DCIS, evenwith perfect (i.e. biologically relevant) deﬁnitions and
classiﬁcation systems, a 100% agreement will never be reached, as
histological examination is not an absolute science. Hopefully the
integration of various clinical, radiological, histological, and mo-
lecular markers will improve our ability to reliably distinguish
between low- and high-risk lesions.
A DCIS diagnosis comes with a chance missing invasive breast
cancer
Invasive breast cancer has been found in 8e43% of resection
specimens from patients who were primarily diagnosed with DCIS
based on a preoperative biopsy [49e58]. At least some of these
highly variable numbers can be explained by differences in the size
and quantity of biopsies taken as well as by the use of different
imaging techniques. In addition, it is essential to be informed about
why the biopsy was taken. This is illustrated by the fact that the risk
of upgrade will be higher when mass lesions or architectural dis-
tortions are found on imaging compared to calciﬁcations only
[49,51,53,55,57,58]. Most studies also agree that larger lesions e
based on the effect of size on imaging diagnosis e carry a higher
upgrade risk than smaller ones [49e52,55,59]. Paradoxically, the
upgrade risk for smaller tumours is higher, because the sensitivity
of mammographically detecting tumours of only 0,5 cm is low
(<30%) and high (>90%) for tumours of 1,0 cm [60]. In some studies
a higher grade of DCIS was a signiﬁcant predictor of upgrade with
an upgrade occurring in only 6e7% of patients versus 13e31% for
low and intermediate/high grade respectively [52e54,58]. Others
found grade not to be predictive [49e51,53,55].Please cite this article in press as: Groen EJ, et al., Finding the balance betw
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Among health care providers as well as among women with
DCIS, considerable uncertainties exist regarding the degree of risk
involved for developing invasive breast cancer. In general, DCIS has
a relative risk (RR) of 8e11 for subsequent development of invasive
carcinoma [22,34]. DCIS in itself has an excellent long-term breast
cancer-speciﬁc survival exceeding 98% after 10 years of follow-up
[1,61,62]. Strikingly, grade was not signiﬁcantly associated with
the risk of local recurrence.
Factors associated with DCIS progression to invasive breast
carcinoma remain poorly deﬁned, because most patients are
treated in order to completely eradicate the lesion [63]. Several
studies have shown that high-grade DCIS has a higher probability of
ipsilateral invasive breast cancer than low-grade DCIS. One of the
largest studies is that conducted by The Eastern Cooperative
Oncology Group (ECOG). This non-randomized prospective study
included 670 patients with either low/intermediate grade DCIS or
high-grade DCIS who underwent complete excision. At a median
follow-up of 6.7 years, the low-intermediate group had a 10.5% risk
of local relapse, whereas the high-grade group had an 18% recur-
rence rate, of which 35% were invasive breast cancers [13].
Our group analysed an unbiased, large population-based,
nation-wide cohort, comprising 10,090 women with a primary
diagnosis of DCIS between 1989 and 2004 (Elshof et al., submitted).
In total, 5.8% developed ipsilateral invasive recurrence after treat-
ment for DCIS (breast sparing or mastectomy) after a median
follow-up of 11.6 years (Elshof et al., submitted). Narod and co-
workers analysed the SEER database and showed that women
younger than 35 and women of African-American descent have a
higher risk of invasive recurrence and death [18]. Ameta-analysis of
four randomized clinical trials to investigate the role of radio-
therapy in BCT for DCIS after a complete local excision of the lesion
showed a 50% reduction in the risk of local recurrence with half of
these recurrences being invasive, but has no effect on breast cancer-
speciﬁc mortality [15].
Taken together, these studies provide a generalized estimation
of how large the risk is that DCIS progresses into invasive breast
cancer, but without allowing individualized prediction.
Current DCIS management is at the safe side
In DCIS, prognosis is based on the risk of (invasive) local recur-
rence, although such risk estimations are far from precise as
described above. If the lesion is not too extensive, breast-
conserving treatment for DCIS is frequently recommended,
resulting in 60e70% of women being suitable for this therapy [64].
If the lesion is too extensive, a mastectomy with or without im-
mediate reconstruction is generally advised. Radiotherapy after
surgery is nowadays standard treatment for DCIS, as randomized
controlled trials have demonstrated a 50% reduction in ipsilateral
breast cancer risk [15]. For tamoxifen use there is no consensus if
there is any absolute survival beneﬁt that outweighs the harm of
long term endocrine treatment [65,66].
According to Dutch, English, and American guidelines and based
on higher upgrade risks, indications for a sentinel lymph node bi-
opsy (SLNB) in DCIS patients planning to undergo breast sparing
surgery include a palpable mass, age below 55 years, intermediate
or high grade DCIS, and a solid mass or a lesion larger than 25 mm
or extensive calciﬁcations on imaging (see e.g. www.oncoline.nl).
As a SLNB is less reliable after mastectomy, it is also recommended
for all patients treated by mastectomy.
Strikingly, there is a tendency towards minimizing axiliary
surgery for invasive breast cancer [67,68]. There are now even trials
investigating whether a SLNB can be left out of treatment ofeen over- and under-treatment of ductal carcinoma in situ (DCIS), The
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date, no comparable trials have been undertaken for patients with
‘only’ DCIS, while logically, risks seem even lower. It has been
shown that even a positive SLNB in DCIS patients does not affect
survival, although some patients did receive systemic treatment
[70e72]. We need to await more deﬁnitive results indicating that
omitting a SLNB for women with pure DCIS patients is likely to be
safe.
Distinguishing harmless from potentially hazardous DCIS is
challenging
Evidently, overtreatment of harmless DCIS should be prevented,
without compromising the excellent outcomes presently achieved
in DCIS management. This means being able to reliably distinguish
harmless from potentially hazardous DCIS. Therefore, on-goingTable 1
IHC marker selection to determine DCIS to estimate DCIS aggressiveness.
Antigens No. of cases Finding(s)
ER/PR 119 DCIS Presence of PR expression is associated with ex
grade correlated with decrease in ER and PR p
118 pure DCIS, 100 IBC Invasion is associated with a signiﬁcant increa
95 DCIS A direct positive relationship is observed for th
DCIS.
HER2 180 DCIS HER2neu is regarded as an important prognos
recurrence.
118 pure DCIS, 100 IBC Invasion is associated with a signiﬁcant increa
130 DCIS, 159 DCIS þ IBC No signiﬁcant differences between the gene am
ESR1, CCND1, and MYC. Data suggest an early ro
not in the initiation of invasive tumour growth
226 DCIS cases Data suggests loss of RB can contribute to the
alone is not sufﬁcient to drive invasion into th
loss and drive the phenotype towards EMT.
AR Findings suggest that decreases in AR and and
the increased biological aggressiveness in tripl
Ki-67 324 initial DCIS p16þ COX-2þ and Ki67 þ in DCIS is prognosti
correlation between COX-2 levels and prolifera
36 DCIS þ IBC Multiple DCIS lesions from the same patient fr
markers: PR, HER2, Ki-67, and p16. Individuals
Ki-67, increased mutant p53 and low p16 shou
p53 118 pure DCIS, 100 IBC Invasion is associated with a signiﬁcant increas
more frequent in high-grade DCIS.
103 DCIS Expression of mutant p53 is associated with hi
DCIS lesions.
36 DCIS þ IBC Multiple DCIS lesions from the same patient fr
markers: PR, HER2, Ki-67, and p16. Individuals
Ki-67, increased mutant p53 and low p16 shou
p16 324 initial DCIS p16þ COX-2þ and Ki67 þ in DCIS is prognosti
50 DCIS, 50 IDC, 50 benign Luminal lesions of DCIS with high p16 are mor
luminal A breast cancer is associated with prog
40 UDH, 20 FEA, 40 ADH, 40
DCIS
p16INK4a methylation is associated with DCIS
premalignant lesions and carcinomas and may
36 DCIS þ IBC Multiple DCIS lesions from the same patient fr
markers: PR, HER2, Ki-67, and p16. Individuals
Ki-67, increased mutant p53 and low p16 shou
MYC 141 DCIS, 18 DCIS þ IBC High expression of c-myc in DCIS did not predic
trial.
130 DCIS, 159 DCIS þ IBC No signiﬁcant differences between the gene am
ESR1, CCND1, and MYC. Data suggest an early ro
not in the initiation of invasive tumour growth
COX-2 58 pure DCIS Findings suggest that COX-2 may be a predicti
324 initial DCIS P16þ COX-2þ and Ki67 þ in DCIS is prognosti
correlation between COX-2 levels and prolifera
ALDH1 236 DCIS Combination of EZH2 with ALDH1 within the D
ipsilateral breast event and invasive progressio
EZH2 236 DCIS Combination of EZH2 with ALDH1 within the D
ipsilateral breast event and invasive progressio
ANXA 82 IBC þ LN metastasis and
21 DCIS þ IBC
Lack of ANXA1 expression in breast cancer and
events of malignant transformation.
182 cases Signiﬁcant loss of ANXA1 in DCIS and IBC as com
Selected antigens reported to be related with ‘aggressiveness’ of DCIS based on: (1) differe
(3) conﬁrmation in more than 1 research paper.
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nostic biomarkers, applying e.g. immunohistochemistry and
genomic techniques, pursuing the Holy Grail in prediction will be
described below.
A multitude of markers have been implicated in identifying
subgroups of DCIS by immunohistochemistry (IHC; see for a brief
overview Table 1). The most commonly used markers are ER, PR,
HER2, and Ki67. As in invasive breast cancer, they are sometimes
used to determine the subtype and ‘aggressiveness’ of DCIS.
Expression of the hormone receptors, a low-grade, and a low
percentage of Ki67-positive cells in DCIS are related to a lower rate
of invasive recurrence and/or lower grade [4,73e75]. In general,
overexpression of HER2 is associated with higher recurrence rates
[74]. Besides the usual markers, expression of p16 and p53 is
related to a higher local recurrence rate [4,76e79]. COX-2 is
related to proliferation and as such risk on local recurrence [4,79].Reference
pression of ER and lack of comedo-necrosis in DCIS. Increasing tumour
ositivity. Comedo-necrosis is associated with ER and PR negativity.
[107]
se in Ki67 expression and decreases in ER, PR and Her-2 expression. [73]
e expression of ER, PR and Bcl-2 negativity for the clinical recurrence of [75]
tic and predictive marker, with its overexpression predicting local [74]
se in Ki67 expression and decreases in ER, PR and Her-2 expression. [73]]
pliﬁcation status of DCIS and invasive breast cancer concerning HER2,
le of all analysed gene ampliﬁcations in breast cancer development but
.
[108]
function of ErbB2 (HER2) in driving disease progression. ErbB2 (HER2)
e surrounding matrix. RB deﬁciency potentially cooperates with ErbB2
[109]
rogen-metabolising enzymes (17bHSD5 and 5aR1) may be involved in
e-negative breast cancer. Also relating to triple-neg DCIS.
[110]
c for recurrence/invasive cancer and suggests that the biological
tion may be signiﬁcant.
[4]
equently exhibit heterogeneity in the expression of clinically relevant
with a heterogeneous DCIS cell population combined with high levels of
ld be clinically managed more aggressively.
[77]
e in Ki67 expression and decreases in ER, PR and Her-2 expression. P53 [73]
gh expression of VEGF and correlates with biological aggressiveness of [111]
equently exhibit heterogeneity in the expression of clinically relevant
with a heterogeneous DCIS cell population combined with high levels of
ld be clinically managed more aggressively.
[77]
c for recurrence of DCIS and/or invasive cancer. [4]
e likely to develop into aggressive breast cancer. p16 expression in
ression from DCIS to IDC.
[78]
, plays an important role in the initiation and progression of
be a crucial event in cell transformation.
[112]
equently exhibit heterogeneity in the expression of clinically relevant
with a heterogeneous DCIS cell population combined with high levels of
ld be clinically managed more aggressively.
[77]
t local recurrence, but still is of interest. Has to be conﬁrmed in a larger [113]
pliﬁcation status of DCIS and invasive breast cancer concerning HER2,
le of all analysed gene ampliﬁcations in breast cancer development but
.
[108]
ve marker of early relapse in with DCIS [79]
c for recurrence/invasive cancer and suggests that the biological
tion may be signiﬁcant.
[4]
CIS epithelial compartment is associated with the prognosis for
n.
[114]
CIS epithelial compartment is associated with the prognosis for
n.
[114]
early loss of ANXA1 in DCIS, suggests a possible role for ANXA1 in early [80]
pared to normal. ANXA1 overexpression was correlated with poor RFS. [81]
ntial expression of the antigen between DCIS and IDC; (2) multivariable signiﬁcance;
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in variable mechanisms related to cancer development and
progression. Loss of ANXA1 expression, as observed in the
majority of breast cancers, seems to be related to early events of
malignant transformation. However, overexpression was
shown to be associated with poor relapse free survival [80,81].
Interestingly, intra-individual DCIS heterogeneity (high Ki67,
mutant p53, and low p16) is associated with more aggressive DCIS
[77]. This is relevant for the interpretation of further genomic
proﬁling of DCIS.
However, the impact of most of these studies is limited, as they
involve small patient series relate to series with an adjacent inva-
sive component and are therefore not ‘pure DCIS’, and information
on follow up is also often lacking [82,83].
In recent years, several studies have also focused on ﬁnding
molecular markers associated with aggressiveness in DCIS [28].
The use of laser capture microdissection to harvest deﬁned cell
populations has proven essential for the study of DCIS. Studies on
DCIS and an adjacent invasive component have shown that mo-
lecular characteristics associated with invasiveness are already
present in the DCIS lesion [84,85]. Petridis and co-workers
showed that shared genetic susceptibility exists for DCIS and
invasive ductal carcinoma (IDC) and that studies with larger
numbers are needed to determine if IDC or DCIS speciﬁc loci exists
[86]. Gene expression analysis has shown that pre-invasive le-
sions and invasive breast cancer display remarkable similar gene
expression patterns [85]. Carraro et al. summarized differently
expressed genes associated with aggressive behaviour of DCIS
lesions [87]. Genes belonging to cell signalling (i.e. CDH1), cellular
movement (MMPs), growth and proliferation are involved. Other
studies focus on speciﬁc copy number alterations. 16q loss is
found in the majority of low-grade DCIS lesions, while more
complex karyotypes are observed in high-grade lesions. Speciﬁc
copy number aberrations reported to be associated with DCIS are
ampliﬁcations of MYC, FGFR1 and CCND1) [88]. Complicating
factors in the studies employed so far are the low numbers of
samples studied and the heterogeneity between lesions and
within the lesions [89,90].
The Oncotype DX DCIS score is the ﬁrst multi-gene assay that
has been claimed to be validated in an independent study [91]. This
score predicts both the risk of an in situ and invasive recurrence but
still assumes that every DCIS should be treated by surgery, as the
assay merely indicates patients having beneﬁt from radiotherapy.
Prospective validation of this assay has not been done yet.
Taken together, a conclusive set of biomarkers suitable for
implementation in routine clinical practice has not been identiﬁed
yet. Campbell et al. therefore argued for the development of a “Pre-
Cancer Genome Atlas” to gain insight in the earliest molecular and
cellular events associated with cancer initiation which eventually
will enable us to ﬁnd biomarkers for risk stratiﬁcation.
Solving the DCIS dilemma requires integrated and novel
approaches
Current pathology has limited additional value for more
nuanced clinical practice when dealing with DCIS, its diagnosis and
consequences for the women involved. We need to more seriously
consider opportunities for integrated and novel approaches. To
prioritize DCIS research, the US Patient-Centred Outcomes
Research Institute commissioned a study to do so [92]. Stake-
holders prioritized evidence gaps related to incorporation of
patient-centred outcomes into future studies on DCIS, develop-
ment of better methods to predict risk for invasive cancer, evalu-
ation of a strategy of active surveillance, and testing of decision-
making tools.Please cite this article in press as: Groen EJ, et al., Finding the balance betw
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well annotated retrospective data sets, enabling integration of
clinical, morphological and molecular features. Strikingly, such an
integrative approach is not available yet. Ultimately, such tools
should be able to distinguish harmless from potentially hazardous
screen-detected DCIS and help clinicians and women with DCIS to
decide between management using active surveillance or more
intensive treatment. For this, data from population-based
screening, hospital records, cancer registries, pathology, current
and upcoming molecular and biological techniques should be in-
tegrated in a stepwise manner:
1. Compile representative DCIS patient cohorts and collect all neces-
sary data and material. Better methods to predict DCIS risk rely
on large series of clinical data and tissue blocks for histopath-
ologic and molecular analysis. Such studies have started in the
Netherlands with the collection of a large nationwide,
population-based, retrospective study (n¼ 10,090) (Elshof et al.,
submitted). Clinical, radiological and molecular data will be in-
tegrated and compared between women with DCIS who may or
may not have developed an ipsilateral invasive recurrence after
breast-conserving treatment, during a follow up period of more
than 10 years. The excellent registration in the Netherlands at
the Dutch Cancer Registry (NKR), the breast cancer screening
and PALGA (Pathology National Automated Archive) is unique in
the world and enables reliable and makes complete data
collection possible. Another huge effort is the Sloane Project, a
UK wide prospective audit of screen detected non-invasive and
atypical hyperplasia of the breast. All UK NHS Breast Screening
Units are invited to participate. It is a multi-disciplinary project
involving radiologists, pathologists, surgeons and oncologists.
Detailed follow up data of all DCIS detected by the NHS Breast
Screening Programwill be collected such as information on local
recurrence, contralateral cancer, metastases, and death, as well
as data on screening and treatment, and most importantly for
biomarker research, tissue blocks will be collected, enabling
molecular pathology studies (www.sloaneproject.co.uk).
2. Find and validate molecular markers related to outcome. To obtain
reliable, detailed results, DCIS should be analysed applying
immunohistochemistry and genomic analysis on resection
specimens, as the size of the biopsies is too small for these an-
alyses. For these analyses, laser microdissection or alternative
strategies should be used to capture the cells and tissue regions
of interest at high speciﬁcity. Comprehensive genomic charac-
terisation has to be done to understand the biological properties
of DCIS that contribute to the evolution and ’aggressiveness' of
DCIS. This includes complete description of all drivers and mu-
tation signatures in DCIS, exploring intralesional heterogeneity
in DCIS, and ﬁnding putative associations between mutation
signatures (see [93]) and the risk of progression into invasive
breast cancer. By this means, clonal evolution, evolutionary
pathways, and rare events in DCIS related to outcome (recur-
rence, progression to invasive disease) can be characterized. In
addition, we can also test if genetic and microenvironmental
diversity, including immune responses [94], provide universal
biomarkers, helping to predict progression to invasive disease.
This innovative approach could yield a universally applicable
construct for understanding interactions between precancerous
lesions and their environments.
3. Apply innovative molecular imaging technologies to understand
the transition of DCIS into invasive breast cancer. The missing link
in the full molecular picture can be obtained by analysing sub-
regions of a DCIS lesion, e.g. by applying Mass Spectrometry
Imaging (MSI), as this technique can be successfully applied on
formalin-ﬁxed, parafﬁn-embedded tissue [95]. Our preliminaryeen over- and under-treatment of ductal carcinoma in situ (DCIS), The
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tative genomic markers in DCIS. Perhaps only a small part of the
DCIS lesion has invasive potential, which means our tools need
to be able to detect molecular differences within the lesion.
Most likely, MSI has vital additional value in combination with
advanced bioinformatics and statistical analysis, to characterize
intralesional heterogeneity to determine phenotypes based onTable 2
Comparison of the designed and initiated prospective, randomised, open-label, phase III,
The information provided is based on literature for the LORIS and LORD trial [19,96] and
Trial name LORD LORIS
Clariﬁcation
acronym/
trial name
Low risk DCIS Low risk DCIS
Trial status Recruitment will start in 2016 Recruiting from July 2014
Setting and
locations
Mainland Europe (n > 30) United Kingdom (n > 20)
Inclusion
criteria
Women  45 years with
asymptomatic, pure low-grade DCIS
based on representative vacuum-
assisted biopsies (at least 6) of
unilateral, calciﬁcations only of any
size detected by population-based or
opportunistic screening
mammography.
Women  46 years with
asymptomatic pure, non-high gr
DCIS (e.g. low grade DCIS and
intermediate grade DCIS with lo
grade features) based on vacuum
assisted core biopsies of screen-
detected or incidental calciﬁcati
only of any size (uni-/bilateral).
Exclusion
criteria
No prior history of DCIS or invasive
breast cancer, a BRCA 1/2 gene
mutation present in family, no
bilateral DCIS, synchronous
contralateral invasive breast cancer,
lobular carcinoma in situ, Paget's
disease, or invasive breast disease on
cytology/histology
No prior history or current diag
of invasive breast cancer or ipsila
DCIS and no high risk group for
developing breast cancer
Central review No central review of pathology. Real time central review of
histological slides by expert DCI
pathologists.
Interventions Randomisation between standard
treatment according to local policy
(wide local excision with/without
radiotherapy, mastectomy and
possibly hormonal therapy by
Tamoxifen) and active surveillance.
Both study arms will be monitored
with annual digital mammography
for 10 years.
Randomisation between standar
surgical and adjuvant treatment
according to local policy and
active surveillance, with speciﬁc
notiﬁcation that patients in the
latter group should not receive
anti-oestrogen treatment.
Both study arms will be monito
with annual mammography for
10 years. Anti-oestrogen treatm
not allowed in the active surveil
arm.
Randomisation Allocation ratio 1:1 Allocation ratio 1:1
Primary end-
points
Safety will be measured by ipsilateral
invasive breast cancer-free
percentage at 5 and 10 years.
Safety will be measured by ipsila
invasive breast cancer-free surv
time at 5 and 10 years.
Secondary
end-points
- Rate of invasive disease or DCIS
grade 2/3 at ﬁnal pathology
specimen
- Time to ipsilateral grade II or III
DCIS and time to contralateral DCIS
- Cumulative incidence of
contralateral invasive breast cancer
- Ipsilateral mastectomy rate
- Biopsy rate during follow-up
- Time to failure of active
surveillance strategy
- Distant metastases free interval
- Overall survival
- Central collection of imaging data
and biosamples for translational
research purposes
- Patient reported outcomes
- Cost-effectiveness
- Time to development of ipsila
contralateral and any invasive
breast cancer
- Overall survival
- Time to mastectomy or surger
- Quality of Life
- Quality-adjusted life years
- Translational explor
assessment of predictive
biomarkers
- Patient reported outcomes
- Cost-effectiveness
Sample size
needed
1240 patients 932 patients
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olomics, lipidomics, and peptidomics).
4. Integrate clinical, morphological, and molecular data to build a
robust risk stratiﬁcation tool. Associations between clinical,
morphological, andmolecular data should be analysed to build a
model accurately predicting subsequent risk for developing
ipsilateral invasive breast cancer. Candidate risk stratiﬁcationnon-inferiority trials to test whether less intensive treatment of low risk DCIS is safe.
on personal communication for the COMET and LARRIKIN trial.
COMET LARRIKIN
Comparison of operative versus
medical endocrine therapy for low
risk DCIS
The Australian slang word ‘larrikin’ is
associated with the Australian
identity: a bloke who refuses to stand
on ceremony.
Not yet recruiting Funding request submitted
United States (n ¼ 100) Australia and New Zealand (n  12)
ade
w
ons
Women  40 years with pure, non-
mass forming low-risk DCIS, e.g. ER þ
and/or PR þ and HER-2 receptor-
negative grade I or II DCIS based on a
core biopsy without evidence of other
breast disease on physical
examination and breast imaging
within 6 months of registration.
Women  55 years with pure,
asymptomatic and low risk DCIS (low
and intermediate grade) based on
either a core biopsy and/or vacuum-
assisted biopsy or open diagnostic
surgical biopsy of screen detected or
incidental calciﬁcations (uni/bilateral
but unifocal)  20 mm.
nosis
teral
Not known. No previous or current diagnosis of
invasive cancer, previous ipsilateral
DCIS, Paget's disease or LCIS,
pregnancy/lactation or a known
BRCA1/2 mutation
S
Not known. No central review planned.
d
red
ent is
lance
Randomisation between standard
treatment including surgery and
radiation and active surveillance.
Patients in both groups are free to
decide whether to choose endocrine
therapy.
Both study arms will be carefully
monitored with mammograms and
physical exams every 6 months for 5
years.
Randomisation between standard
treatment according to physician and
patient choice (surgery with/without
radiotherapy) and active surveillance.
Patients in both groups are free to
decide whether to opt for endocrine
therapy for 5 years.
Both groups will be monitored with
annual mammography for at least 10
years and regular clinical
examinations or at patient's request
for 5 years then annually.
Allocation ratio 1:1 Allocation ratio 1:1
teral
ival
Safety will be measured by assessing
the invasive cancer rate in the
affected breast at 2 and 5 years.
Safety will be measured by ipsilateral
breast cancer free survival at 5 and 10
years.
teral,
y
atory
- Mastectomy and breast
conservation rate
- Contralateral invasive cancer rate
- Overall and disease speciﬁc
survival
- Breast MRI rate
- Breast biopsy rate
- Radiation rate
- Chemotherapy rate
- Psychosocial outcomes
- Decision quality
- Financial burden/employment
- Rate of invasive disease and higher
grade DCIS in ﬁnal pathology
specimen
- Time to development of ipsilateral
and any invasive breast cancer
- Ipsilateral mastectomy rate at 5
years
- Biopsy rate during follow-up
- Overall survival
- Time to failure of active
surveillance strategy
- Quality of Life
- Cost Effectiveness
1189 patients 550 patients
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retrospective DCIS series and prospective clinical trials. In order
to communicate such a risk prediction model to patients and
doctors, risk calculator software should be developed in analogy
to existing calculators such as adjuvant online (www.
adjuvantonline.com) and the breast cancer risk assessment
tool (http://www.cancer.gov/bcrisktool/). These online tools
have proven themselves to be very helpful and easy to use,
which is essential when incorporated into daily practice.
This ultimately will provide holistic integrative proﬁles per pa-
tient and an innovative multifactorial algorithm able to identify
patients with very low-risk for invasive recurrence, i.e. indolent
DCIS, that can be managed safely by active surveillance only. This
can save many women from the potential physical and psycho-
logical harm of invasive treatment. Evidently, such an approachwill
only be successful if international collaboration between experi-
enced dedicated researchers, clinicians, and patient partners are
well established.
Second, prospective studies on active surveillance should be
conducted to deliver ﬁnal proof that active surveillance is safe for
DCIS already known to be low-risk. For example, the international
LORD trial ('low risk DCIS), which will start to recruit women with
low grade DCIS in Europe in 2016 under the auspices of the Euro-
pean Organisation for Research and Treatment of Cancer (EORTC).
In this study, women with 'pure' low-grade DCIS detected at
screening based on calciﬁcations are randomized to either an
'active surveillance' policy or standard therapy [19]. After inclusion,
womenwill be followed for 10 years and main outcome measure is
the risk of developing invasive breast cancer. If a relapse occurs,
breast-conserving therapy with radiation therapy will still be an
option. By contrast, when a recurrence develops after standard
treatment for DCIS, an ablation is usually the only choice. Similar
studies are the LORIS trial in the UK [96], the COMET trial in the USA
(http://www.pcori.org/research-results/2016/comparison-
operative-versus-medical-endocrine-therapy-low-risk-dcis-
comet), and the Australian LARRIKIN trial for which no detailed
information is available yet (see Table 2).
In moving forward, the following considerations are of para-
mount importance. First, low-grade hormone receptor-positive
invasive breast cancer grows only a few millimetres per year and
a delay in detection will not affect the excellent prognosis inherent
to these tumours [97]. Second, there is convincing evidence that
low grade invasive breast tumours originate from low grade pre-
cursor lesions [84,98e103]. Third, women with low-grade lesions
whomeet these criteria for inclusion in the LORIS trial did not show
any upgrade to invasive cancer [104]. This underlines again that
active surveillance for women with low-grade screen-detected
DCIS is likely to be a safe option, sparing these women the harms of
ineffective treatment, preserving their quality of life.
Adequate communication about DCIS risks involved is key
In general, improving communication about the diagnosis and
prognosis of DCIS patients will likely deliver the most essential
improvements in the management of DCIS. This because there is
much uncertainty about the long-term implications of the diag-
nosis of DCIS (including the risk of invasive breast cancer, thera-
peutic efﬁcacy and safety), making it difﬁcult for patients and
health care providers to make well-informed decisions on treat-
ment options. For a woman, it is difﬁcult to understand that on the
one hand DCIS is a breast cancer precursor but not yet an invasive
disease, and on the other hand that intensive treatment is neces-
sary. It is essential to better assess the risks involved and put these
into perspective, taking into account the quality of life andPlease cite this article in press as: Groen EJ, et al., Finding the balance betw
Breast (2016), http://dx.doi.org/10.1016/j.breast.2016.09.001competitive factors in terms of morbidity and mortality. Educating
health care providers and developing a risk prediction model will
contribute to this better understanding. It has been shown for
prostate cancer, that such a strategy is well-accepted [105,106].
Conclusion
The incidence of DCIS has increased substantially. The rationale
of DCIS treatment is mortality reduction as a result of invasive
breast carcinoma. However, ‘pure' DCIS (without any invasive
component) usually shows no symptoms and does not cause
mortality. We know that a signiﬁcant proportion of the DCIS lesions
will never lead to invasive breast cancer. But right now we don't
know which DCIS lesions will progress and which will not. The
result of this knowledge gap is that every DCIS lesion is treated
similar to invasive breast cancer. Risk stratiﬁcation is therefore
essential for making better-informed treatment decisions. In
addition, large randomized clinical trials are necessary to investi-
gate if active surveillance is an option for low grade DCIS. Last but
not least, communicating in a correct and nuanced manner about
the implications of the diagnosis of DCIS is essential for a realistic
risk perception and optimal decision-making by the patient and the
health care professionals involved.
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